HDAC isoenzyme expression is deregulated in chronic lymphocytic leukemia B-cells and has a complex prognostic significance

References

• Workman JL, Kingston RE. Alteration of nucleosome structure as a mechanism of transcriptional regulation. Annu Rev Biochem 1998; 67:545 - 79; http://dx.doi.org/10.1146/annurev.biochem.67.1.545; PMID: 9759497
   PubMed Web of Science ®Google Scholar
• Forsberg EC, Bresnick EH. Histone acetylation beyond promoters: long-range acetylation patterns in the chromatin world. Bioessays 2001; 23:820 - 30; http://dx.doi.org/10.1002/bies.1117; PMID: 11536294
   PubMed Web of Science ®Google Scholar
• Minucci S, Pelicci PG. Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer. Nat Rev Cancer 2006; 6:38 - 51; http://dx.doi.org/10.1038/nrc1779; PMID: 16397526
   PubMed Web of Science ®Google Scholar
• Witt O, Deubzer HE, Milde T, Oehme I. HDAC family: What are the cancer relevant targets?. Cancer Lett 2009; 277:8 - 21; http://dx.doi.org/10.1016/j.canlet.2008.08.016; PMID: 18824292
   PubMed Web of Science ®Google Scholar
• Secrist JP, Zhou X, Richon VM. HDAC inhibitors for the treatment of cancer. Curr Opin Investig Drugs 2003; 4:1422 - 7; PMID: 14763127
   PubMedGoogle Scholar
• Weichert W. HDAC expression and clinical prognosis in human malignancies. Cancer Lett 2009; 280:168 - 76; http://dx.doi.org/10.1016/j.canlet.2008.10.047; PMID: 19103471
   PubMed Web of Science ®Google Scholar
• Hamblin T. Chronic lymphocytic leukaemia: one disease or two?. Ann Hematol 2002; 81:299 - 303; http://dx.doi.org/10.1007/s00277-002-0476-1; PMID: 12107557
   PubMed Web of Science ®Google Scholar
• Van Bockstaele F, Verhasselt B, Philippé J. Prognostic markers in chronic lymphocytic leukemia: a comprehensive review. Blood Rev 2009; 23:25 - 47; http://dx.doi.org/10.1016/j.blre.2008.05.003; PMID: 18599169
   PubMed Web of Science ®Google Scholar
• Stamatopoulos B, Meuleman N, De Bruyn C, Mineur P, Martiat P, Bron D, et al. Antileukemic activity of valproic acid in chronic lymphocytic leukemia B cells defined by microarray analysis. Leukemia 2009; 23:2281 - 9; http://dx.doi.org/10.1038/leu.2009.176; PMID: 19710697
   PubMed Web of Science ®Google Scholar
• Stamatopoulos B, Meuleman N, De Bruyn C, Delforge A, Bron D, Lagneaux L. The histone deacetylase inhibitor suberoylanilide hydroxamic acid induces apoptosis, down-regulates the CXCR4 chemokine receptor and impairs migration of chronic lymphocytic leukemia cells. Haematologica 2010; 95:1136 - 43; http://dx.doi.org/10.3324/haematol.2009.013847; PMID: 20145270
   PubMed Web of Science ®Google Scholar
• Stimson L, Wood V, Khan O, Fotheringham S, La Thangue NB. HDAC inhibitor-based therapies and haematological malignancy. Ann Oncol 2009; 20:1293 - 302; http://dx.doi.org/10.1093/annonc/mdn792; PMID: 19515748
   PubMed Web of Science ®Google Scholar
• Caligaris-Cappio F, Ghia P. The normal counterpart to the chronic lymphocytic leukemia B cell. Best Pract Res Clin Haematol 2007; 20:385 - 97; http://dx.doi.org/10.1016/j.beha.2007.02.005; PMID: 17707828
   PubMed Web of Science ®Google Scholar
• Farren TW, Giustiniani J, Liu FT, Tsitsikas DA, Macey MG, Cavenagh JD, et al. Differential and tumor-specific expression of CD160 in B-cell malignancies. Blood 2011; 118:2174 - 83; http://dx.doi.org/10.1182/blood-2011-02-334326; PMID: 21715317
   PubMed Web of Science ®Google Scholar
• Gutierrez AJ Jr., Tschumper RC, Wu X, Shanafelt TD, Eckel-Passow J, Huddleston PM 3rd, et al. LEF-1 is a prosurvival factor in chronic lymphocytic leukemia and is expressed in the preleukemic state of monoclonal B-cell lymphocytosis. Blood 2010; 116:2975 - 83; http://dx.doi.org/10.1182/blood-2010-02-269878; PMID: 20595513
   PubMed Web of Science ®Google Scholar
• Gary-Gouy H, Sainz-Perez A, Marteau JB, Marfaing-Koka A, Delic J, Merle-Beral H, et al. Natural phosphorylation of CD5 in chronic lymphocytic leukemia B cells and analysis of CD5-regulated genes in a B cell line suggest a role for CD5 in malignant phenotype. J Immunol 2007; 179:4335 - 44; PMID: 17878328
   PubMed Web of Science ®Google Scholar
• Saunders FK, Lawry J, Winfield DA, Goepel JR, Hancock BW, Sharrard RM, et al. Comparison of protein synthesis profiles in chronic lymphocytic leukaemia cells and B-lymphocytes from peripheral blood, cord blood and tonsil. Experientia 1994; 50:493 - 6; http://dx.doi.org/10.1007/BF01920755; PMID: 7515011
   PubMedGoogle Scholar
• Zhang Z, Yamashita H, Toyama T, Sugiura H, Omoto Y, Ando Y, et al. HDAC6 expression is correlated with better survival in breast cancer. Clin Cancer Res 2004; 10:6962 - 8; http://dx.doi.org/10.1158/1078-0432.CCR-04-0455; PMID: 15501975
   PubMed Web of Science ®Google Scholar
• Ashraf N, Zino S, Macintyre A, Kingsmore D, Payne AP, George WD, et al. Altered sirtuin expression is associated with node-positive breast cancer. Br J Cancer 2006; 95:1056 - 61; http://dx.doi.org/10.1038/sj.bjc.6603384; PMID: 17003781
   PubMed Web of Science ®Google Scholar
• Sakuma T, Uzawa K, Onda T, Shiiba M, Yokoe H, Shibahara T, et al. Aberrant expression of histone deacetylase 6 in oral squamous cell carcinoma. Int J Oncol 2006; 29:117 - 24; PMID: 16773191
   PubMed Web of Science ®Google Scholar
• Ouaïssi M, Sielezneff I, Silvestre R, Sastre B, Bernard JP, Lafontaine JS, et al. High histone deacetylase 7 (HDAC7) expression is significantly associated with adenocarcinomas of the pancreas. Ann Surg Oncol 2008; 15:2318 - 28; http://dx.doi.org/10.1245/s10434-008-9940-z; PMID: 18506539
   PubMed Web of Science ®Google Scholar
• Skov V, Larsen TS, Thomassen M, Riley CH, Jensen MK, Bjerrum OW, et al. Increased gene expression of histone deacetylases in patients with Philadelphia-negative chronic myeloproliferative neoplasms. Leuk Lymphoma 2012; 53:123 - 9; http://dx.doi.org/10.3109/10428194.2011.597905; PMID: 21806350
   PubMed Web of Science ®Google Scholar
• Bradbury CA, Khanim FL, Hayden R, Bunce CM, White DA, Drayson MT, et al. Histone deacetylases in acute myeloid leukaemia show a distinctive pattern of expression that changes selectively in response to deacetylase inhibitors. Leukemia 2005; 19:1751 - 9; http://dx.doi.org/10.1038/sj.leu.2403910; PMID: 16121216
   PubMed Web of Science ®Google Scholar
• Wang JC, Kafeel MI, Avezbakiyev B, Chen C, Sun Y, Rathnasabapathy C, et al. Histone deacetylase in chronic lymphocytic leukemia. Oncology 2011; 81:325 - 9; http://dx.doi.org/10.1159/000334577; PMID: 22237050
   PubMed Web of Science ®Google Scholar
• Marquard L, Gjerdrum LM, Christensen IJ, Jensen PB, Sehested M, Ralfkiaer E. Prognostic significance of the therapeutic targets histone deacetylase 1, 2, 6 and acetylated histone H4 in cutaneous T-cell lymphoma. Histopathology 2008; 53:267 - 77; http://dx.doi.org/10.1111/j.1365-2559.2008.03109.x; PMID: 18671804
   PubMed Web of Science ®Google Scholar
• Osada H, Tatematsu Y, Saito H, Yatabe Y, Mitsudomi T, Takahashi T. Reduced expression of class II histone deacetylase genes is associated with poor prognosis in lung cancer patients. Int J Cancer 2004; 112:26 - 32; http://dx.doi.org/10.1002/ijc.20395; PMID: 15305372
   PubMed Web of Science ®Google Scholar
• Jung KH, Noh JH, Kim JD, Eun JW, Bae JH, Chang Y, et al. HDAC6 functions as a tumor suppressor by activating JNK-mediated beclin 1-dependent autophagic cell death in liver cancer. Hepatology 2012; 56:644 - 57; http://dx.doi.org/10.1002/hep.25699; PMID: 22392728
   PubMed Web of Science ®Google Scholar
• Bosch-Presegué L, Vaquero A. The dual role of sirtuins in cancer. Genes Cancer 2011; 2:648 - 62; http://dx.doi.org/10.1177/1947601911417862; PMID: 21941620
   PubMedGoogle Scholar
• Van Meter M, Mao Z, Gorbunova V, Seluanov A. SIRT6 overexpression induces massive apoptosis in cancer cells but not in normal cells. Cell Cycle 2011; 10:3153 - 8; http://dx.doi.org/10.4161/cc.10.18.17435; PMID: 21900744
   PubMed Web of Science ®Google Scholar
• Peters CJ, Rees JRE, Hardwick RH, Hardwick JS, Vowler SL, Ong CA, et al, Oesophageal Cancer Clinical and Molecular Stratification (OCCAMS) Study Group. A 4-gene signature predicts survival of patients with resected adenocarcinoma of the esophagus, junction, and gastric cardia. Gastroenterology 2010; 139:1995 - 2004, e15; http://dx.doi.org/10.1053/j.gastro.2010.05.080; PMID: 20621683
   PubMed Web of Science ®Google Scholar
• Inoue T, Hiratsuka M, Osaki M, Oshimura M. The molecular biology of mammalian SIRT proteins: SIRT2 in cell cycle regulation. Cell Cycle 2007; 6:1011 - 8; http://dx.doi.org/10.4161/cc.6.9.4219; PMID: 17457050
   PubMed Web of Science ®Google Scholar
• Kim HS, Vassilopoulos A, Wang RH, Lahusen T, Xiao Z, Xu X, et al. SIRT2 maintains genome integrity and suppresses tumorigenesis through regulating APC/C activity. Cancer Cell 2011; 20:487 - 99; http://dx.doi.org/10.1016/j.ccr.2011.09.004; PMID: 22014574
   PubMed Web of Science ®Google Scholar
• Park SH, Ozden O, Jiang H, Cha YI, Pennington JD, Aykin-Burns N, et al. Sirt3, Mitochondrial ROS, Ageing, and Carcinogenesis. Int J Mol Sci 2011; 12:6226 - 39; http://dx.doi.org/10.3390/ijms12096226; PMID: 22016654
   PubMed Web of Science ®Google Scholar
• Lucio-Eterovic AKB, Cortez MAA, Valera ET, Motta FJN, Queiroz RGP, Machado HR, et al. Differential expression of 12 histone deacetylase (HDAC) genes in astrocytomas and normal brain tissue: class II and IV are hypoexpressed in glioblastomas. BMC Cancer 2008; 8:243; http://dx.doi.org/10.1186/1471-2407-8-243; PMID: 18713462
   PubMed Web of Science ®Google Scholar
• Zhu C, Chen Q, Xie Z, Ai J, Tong L, Ding J, et al. The role of histone deacetylase 7 (HDAC7) in cancer cell proliferation: regulation on c-Myc. J Mol Med (Berl) 2011; 89:279 - 89; http://dx.doi.org/10.1007/s00109-010-0701-7; PMID: 21120446
   PubMed Web of Science ®Google Scholar
• Park JH, Kim SH, Choi MC, Lee J, Oh DY, Im SA, et al. Class II histone deacetylases play pivotal roles in heat shock protein 90-mediated proteasomal degradation of vascular endothelial growth factor receptors. Biochem Biophys Res Commun 2008; 368:318 - 22; http://dx.doi.org/10.1016/j.bbrc.2008.01.056; PMID: 18211808
   PubMed Web of Science ®Google Scholar
• Castro JE, Prada CE, Loria O, Kamal A, Chen L, Burrows FJ, et al. ZAP-70 is a novel conditional heat shock protein 90 (Hsp90) client: inhibition of Hsp90 leads to ZAP-70 degradation, apoptosis, and impaired signaling in chronic lymphocytic leukemia. Blood 2005; 106:2506 - 12; http://dx.doi.org/10.1182/blood-2005-03-1099; PMID: 15972449
   PubMed Web of Science ®Google Scholar
• Höfling H, Tibshirani R. A study of pre-validation. Ann.Appl.Stat. 2008; 2:643 - 64; http://dx.doi.org/10.1214/07-AOAS152
   Web of Science ®Google Scholar
• Ropero S, Esteller M. The role of histone deacetylases (HDACs) in human cancer. Mol Oncol 2007; 1:19 - 25; http://dx.doi.org/10.1016/j.molonc.2007.01.001; PMID: 19383284
   PubMed Web of Science ®Google Scholar
• Stamatopoulos B, Meuleman N, Haibe-Kains B, Duvillier H, Massy M, Martiat P, et al. Quantification of ZAP70 mRNA in B cells by real-time PCR is a powerful prognostic factor in chronic lymphocytic leukemia. Clin Chem 2007; 53:1757 - 66; http://dx.doi.org/10.1373/clinchem.2007.089326; PMID: 17702857
   PubMed Web of Science ®Google Scholar
• Stamatopoulos B, Meuleman N, De Bruyn C, Pieters K, Anthoine G, Mineur P, et al. A molecular score by quantitative PCR as a new prognostic tool at diagnosis for chronic lymphocytic leukemia patients. PLoS One 2010; 5:5; http://dx.doi.org/10.1371/journal.pone.0012780; PMID: 20862275
   PubMed Web of Science ®Google Scholar
• Montserrat E, Sanchez-Bisono J, Viñolas N, Rozman C. Lymphocyte doubling time in chronic lymphocytic leukaemia: analysis of its prognostic significance. Br J Haematol 1986; 62:567 - 75; http://dx.doi.org/10.1111/j.1365-2141.1986.tb02969.x; PMID: 3954968
   PubMed Web of Science ®Google Scholar
• Döhner H, Stilgenbauer S, Benner A, Leupolt E, Kröber A, Bullinger L, et al. Genomic aberrations and survival in chronic lymphocytic leukemia. N Engl J Med 2000; 343:1910 - 6; http://dx.doi.org/10.1056/NEJM200012283432602; PMID: 11136261
   PubMed Web of Science ®Google Scholar
• Stamatopoulos B, Meuleman N, Haibe-Kains B, Saussoy P, Van Den Neste E, Michaux L, et al. microRNA-29c and microRNA-223 down-regulation has in vivo significance in chronic lymphocytic leukemia and improves disease risk stratification. Blood 2009; 113:5237 - 45; http://dx.doi.org/10.1182/blood-2008-11-189407; PMID: 19144983
   PubMed Web of Science ®Google Scholar